Search Results - Line Nederby
- Showing 1 - 7 results of 7
-
1
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens by Katrine Fladeland Iversen, Line Nederby, Thomas Lund, Torben Plesner
Published in Clinical Hematology International (2022-08-01)Get full text
Article -
2
-
3
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia by Marie Toft-Petersen, Eigil Kjeldsen, Line Nederby, Kirsten Grønbæk, Peter Hokland, Anne Stidsholt Roug
Published in Leukemia Research Reports (2014-01-01)Get full text
Article -
4
-
5
Natural killer cell activity in prostate cancer patients treated with curative radiotherapy with or without androgen deprivation therapy: an observational study by Stine V. Eriksen, Christine V. Madsen, Signe Timm, Ahmed H. Zedan, Louise Raunkilde, Torben F. Hansen, Line Nederby
Published in Acta Oncologica (2025-10-01)Get full text
Article -
6
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy by Sinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, Christa Haugaard Nyhus, Lisbeth Bertelsen, Anders Jakobsen, Torben Schjødt Hansen, Line Nederby
Published in Scientific Reports (2024-04-01)Get full text
Article -
7
Description of an activity-based enzyme biosensor for lung cancer detection by Paul W. Dempsey, Cristina-Mihaela Sandu, Ricardo Gonzalezirias, Spencer Hantula, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann, Alykhan S. Nagji, Nirmal K. Veeramachaneni, Nezih O. Ermerak, Derya Kocakaya, Tunc Lacin, Bedrittin Yildizeli, Patrick Lilley, Sara W. C. Wen, Line Nederby, Torben F. Hansen, Ole Hilberg
Published in Communications Medicine (2024-03-01)Get full text
Article
